Endothelial dysfunction, obesity and insulin resistance.
Obesity is a metabolic disorder of increasing prevalence worldwide and a risk factor for the development of insulin resistance (IR), metabolic syndrome and type 2 diabetes. Obesity is related to endothelial dysfunction through indirect mechanisms such as IR and the associated risk factors, and through direct mechanisms including the production of proinflammatory adipokines and elevated levels of free fatty acids (FFAs) by adipose tissue. Both clinical and experimental studies using genetic and diet-induced animal models of obesity have consistently shown impaired metabolic, agonistor flow-induced vasodilatations correlated with the amount of visceral adipose tissue and improved by dietary interventions and exercise. Compromised bioavailability of NO due to oxidative stress emerges as a main cause of endothelial dysfunction in obesity. Inflamed adipose tissue due to hypoxia, and in particular perivascular adipose tissue (PVAT), secrete larger amounts of reactive oxygen species (ROS) and adipokines that deteriorate NO signaling pathways. Abnormal production and activity of the vasoconstrictor/proatherogenic peptide endothelin-1 (ET-1) is also a hallmark of the obesity- associated endothelial dysfunction. Obesity, and in particular visceral obesity, is one of the main causes of IR, and the pathogenic factors that induce endothelial dysfunction in the earlier stages of obesity will further deteriorate the insulin signaling pathways in endothelial cells thus leading to blunted vasodilatation and abnormal capillary recruitment and substrate delivery by insulin to the target tissues. The present review is an attempt to summarize the current knowledge and the latest novel findings on the pathogenic mechanisms underlying endothelial dysfunction in obesity, in particular the local contribution of oxidative stress and inflammatory response from PVAT, and its role in the obesity-associated cardiovascular and metabolic complications.
Dolores
D
Prieto
Cristina
C
Contreras
Department of Physiology, Faculty of Pharmacy, Universidad Complutense, 28040-Madrid, Spain. dprieto@farm.ucm.es.
Ana
A
Sánchez
D054392:Adipokines / Q000276:immunology; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000276:immunology / Q000378:metabolism; D019332:Endothelin-1 / Q000378:metabolism; D004730:Endothelium, Vascular / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology*; D006801:Humans; D007333:Insulin Resistance / Q000276:immunology; D009569:Nitric Oxide / Q000378:metabolism; D009765:Obesity / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology*; D018384:Oxidative Stress / Q000276:immunology / Q000502:physiology; D017382:Reactive Oxygen Species / Q000378:metabolism; D012307:Risk Factors; D014661:Vasoconstriction / Q000276:immunology / Q000502:physiology; D014664:Vasodilation / Q000276:immunology / Q000502:physiology
D054392:Adipokines; D019332:Endothelin-1; D017382:Reactive Oxygen Species; D009569:Nitric Oxide